Comparative Pharmacology
Head-to-head clinical analysis: DILOR 400 versus MAXAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILOR 400 versus MAXAIR.
DILOR-400 vs MAXAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular cAMP and cGMP, resulting in bronchodilation and vasodilation.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular cAMP.
400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.
2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.
None Documented
None Documented
3.1 hours (terminal elimination half-life; may increase in hepatic impairment or congestive heart failure)
3.5–4.0 hours; clinically, this supports dosing every 4–6 hours as needed.
Renal (70% unchanged), hepatic metabolism (30%)
Renal excretion of unchanged drug accounts for approximately 90% of elimination; fecal excretion is minimal (<5%).
Category C
Category C
Bronchodilator
Bronchodilator